WOODLAND, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCQB: GNVR), a pioneer in AI-accelerated peptide technology for sustainable agriculture, today announced that Chad Pawlak, Chief Executive Officer, will present live at Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com, on December 11th. DATE: December 11th TIME: 12:30 pm ETLINK: REGISTER HEREAvailable for 1x1 meetings following the presentation. Schedule 1x1 Meetings here This will be a live, interactive online e ...

Core Insights - Genvor, Inc. has been granted U.S. Patent No. 12,458,684 for transgenic corn expressing antifungal peptide AGM182, aimed at combating fungal infections in maize [1][2][3] Company Overview - Genvor is focused on AI-accelerated peptide technology for sustainable agriculture, utilizing its proprietary BioCypher™ Algorithm to design next-generation antimicrobial peptides [1][6] - The company aims to provide scalable agricultural solutions that enhance crop protection and optimize agricultural outcomes [6] Patent Details - The patent covers biological compositions that reduce Aspergillus flavus, a fungal pathogen that produces aflatoxins, which can contaminate corn and other crops [2][4] - Research indicates that the technology also shows activity against other mycotoxin-producing fungi, including those from Fusarium species [2][4] Economic Impact - Economic losses from fungal diseases in corn in the U.S. are estimated between $3 billion to $5 billion annually, considering yield reductions and quality degradation [3] - Aflatoxin contamination can lead to market impacts ranging from approximately $52 million in lower-risk years to as much as $1.68 billion in high-risk years [3] Research Validation - Published research validates the effectiveness of AGM182 in transgenic corn seeds, demonstrating a 76–98% reduction in total aflatoxin contamination without adverse effects on plant growth or yield [5][7] - The technology reflects decades of foundational research and aims to deliver safe and effective peptide technologies for global agriculture [5]

Core Insights - Genvor, Inc. has regained active OTCQB trading status, which will facilitate capital formation as the company scales field trials globally [1][2] - The company is advancing four active research and development collaborations across Europe, Brazil, and the United States, focusing on peptide-based formulations for sustainable agriculture [2][3] Company Developments - Genvor has opened a new laboratory in Woodland, California, to support research and development for foliar and peptide-based formulations [3] - The company is actively collaborating on projects that aim to enhance crop resilience and performance under various field conditions [2][4] Technology and Innovation - Genvor utilizes an AI-accelerated peptide design platform, the BioCypher Algorithm, which integrates computational biology and machine learning to create peptides that improve agricultural outcomes [5] - The company holds 2 issued U.S. patents related to antimicrobial and nutrient-enhancing peptides, with 24 proprietary peptides currently in active development [5]